Viewing Study NCT03852251

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:57 PM
Ignite Modification Date: 2026-02-06 @ 1:06 PM
Study NCT ID: NCT03852251
Status: COMPLETED
Last Update Posted: 2024-08-02
First Post: 2019-02-21
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Sponsor: Akeso
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Gastric Adenocarcinoma View
None Advanced Solid Tumors View
None Gastroesophageal Junction Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None immuno-oncology View
None PD-1/CTLA-4 Bispecific View
None gastric or GEJ adenocarcinoma View
None PD-1 View
None CTLA-4 View